10. BIBLIOGRAFÍA

Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM Tumor-associated proteases and inhibitors in gastric

Andreasen PA, Egelund R, Petersen HH.The plasminogen activation system in tumorgrowth, invasion, and metastasis.Cell Mol Life Sci. 2000;57(1):25-40.

Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth.Oncogene. 2004;23(41):6986-90.

Barth AI, Näthke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signaling pathways. Curr Opin Cell Biol. 1997 Oct; 9(5):683-90

Bibbo M, Longatto A. Aspectos Clínicos e Laboratoriais dos derrames cavitários:Conduta Terapêutica e Avaliações Diagnósticas e Prognosticas. Fernando C. Schmitt & Carla Costa. :Biologia Celular. 1th ed. Rio de Janeiro: Revinter, 2001.

Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view Curr Mol Med. 2003;3(7):659-71.

Curiel TJ, Morris C, Brumlik M, Landry SJ, Finstad K, Nelson A, Joshi V, Hawkins C, Alarez X, Lackner A, Mohamadzadeh M. Peptides identified through phage display direct immunogenic antigen to dendritic cells.J Immunol. 2004 ;172(12):7425-31.

Daneri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-Cuellar A, Perez-Montfort R, Orbach-Arbouys S. Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur J Cancer. 1998 ;34(4):566-9

De Vita V, Hellman S, Rosenberg SA. Cancer-Principles and Practice of Oncology. Philadelphia: Lippincot Williams & Wilkins, 2001;Vol 1;134-149.5Th Edition.

Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM.The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.FASEB J. 2002;16(2):147-54.

Duffy MJ. The biochemistry of metastasis. Adv Clin Chem. 1996;32:135-66.

Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60(3):636-43.

Hart IR. Cell adhesión, Motility and Cancer, capítulo 10. En Molecular Biology for Oncologists, editado por Yarnold JR, Stratton M y McMillan TJ. Chapman y Hall, 2ª edición, 1996. 103-111.

Hansen S, Overgaard J, Rose C, Knoop A, Laenkholm AV, Andersen J, Sørensen FB, Andreasen PA. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer. 2003;88(1):102-8.

Riethdorf L, Riethdorf S, Petersen S, Bauer M, Herbst H, Jänicke F, Löning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J Pathol. 1999;189(2):245-50.

Stephens RW, Brünner N, Jänicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer Breast Cancer

cancer: analysis of prognostic impact and individual risk protease patterns Clin Exp Metastasis. 1998;16(1):62-73.

Hazelbag S, Kenter GG, Gorter A, Fleuren GJ. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int J Cancer. 2004;112(6):1020-8.

Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am J Pathol. 1998;153(2):333-9.

Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity- clinical relevance and prognostic value. J Craniomaxillofac Surg. 2005;33(3):191-6.

Kobayashi H, Fujishiro S, Terao T Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res. 1994;54(24):6539-48.

Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci. 2006;63(4):449-68.

Liotta La, Stetler-Stevenson Wg. Principles of molecular cell biology of cancer: cancer metastasis. In De Vita VT et al.: Principles and pratice of oncology. 4th ed. Philadelphia: JB Lippincott, 1993.

Look MP, van Putten WL, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Sweep CG, Ulm K, Peyrat JP, Martin PM et al..Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst. 2002;94(2):116-28.

Machado JC, Soares P, Carneiro F, Rocha A, Beck S, Blin N, Berx G, Sobrinho-Simões M.E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. Lab Invest 1999; 79(4):459-65.

Mueller TJ, Wu H, Greenberg RE, Hudes G, Topham N, Lessin SR, Uzzo RG. Cutaneous metastases from genitourinary malignancies. Urology. 2004;63(6):1021-6.

Nicolson GL, Dulski K, Basson C, Welch DR. Preferential organ attachment and invasion in vitro by B16 melanoma cells selected for differing metastatic colonization and invasive properties. Invasion Metastasis. 1985;5(3):144-58

Nicolson GL. Breast cancer metastasis-associated genes: role in tumour progression to the metastatic state, Institute for Molecular Medicine, Irvine, CA 92614, USA, Biochem Soc Symp. 1998;63:231-43.

Pappot H, Pedersen AN, Brünner N, Christensen IJ. The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: relation to prognosis. Lung Cancer. 2006;51(2):193-200.

Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noel A. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci. 2003;60(3):463-73.

Res Treat. 1998;52(1-3):99-111.

Speleman L, Kerrebijn JD, Look MP, Meeuwis CA, Foekens JA, Berns EM. Prognostic value of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma. Head Neck. 2007;29(4):341-50.